Dialysis exerts significant anti-inflammatory effects through the removal of pro-inflammatory cytokines (IL-6, TNF-α) and uremic toxins that drive chronic inflammation. Regular treatment reduces oxidative stress, lowers C‑reactive protein (CRP) levels, and stabilizes the neutrophil‑to‑lymphocyte ratio. This attenuates the inflammatory burden in cardiorenal syndrome, preserves vascular health, and may improve response to heart failure therapies. However, bio‑incompatibility of membranes can transiently trigger complement activation — but modern biocompatible dialyzers and ultrapure dialysate minimize this, ultimately tipping the balance toward an overall net anti‑inflammatory benefit.